Kayothera founders Dr. Esposito and Dr. Kang as well as Scientific Advisory Board Member Dr. Ganesan today published a perspective on the clinical need for new therapeutics treating advanced cancer patients in Nature Cancer. While many therapies have been developed using progression-free survival and RECIST criteria, too few therapies offer meaningful survival benefits to patients with advanced and metastatic cancers. In this review, the Kayothera team argues that targeting fitness genes and employing new immune activation strategies offers the best potential for long-term, structural changes in how patients with advanced cancer are treated.

At Kayothera, we care deeply about making new therapies that transform outcomes for patients with difficult-to-treat cancers. By developing therapies with the potential to produce deep responses in patients with metastatic or advanced disease, we hope to give patients a new lease on life.

Note: A non-paywall link is available here.